Information Library

Results for: Case Studies - Partnership Structures

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title
  • Focused Co-Promotion

    May 9, 2010
    Roche Italy needed to find new, cost-effective ways to underpin sales of mature products. Uncover what happened when a unique partnership with Quintiles reinforced sales growth.

  • Managing Alliances with the Balanced Scorecard

    January 11, 2010
    “Managing Alliances with the Balanced Scorecard” details how Solvay Pharmaceuticals and Quintiles managed their innovative development alliance to deliver value for both companies.

  • Making the Most of a Smart Move

    March 26, 2009
    In late 2007, Scotland-based ProStrakan Group plc seemed to have everything going for it: four new European product introductions planned for an 18-month period and near-term product launches with an aggregate peak sales potential of $400 to $500 million, both backed by a 340-person pan-European salesforce.

  • Grabbing a Leadership Position

    March 26, 2009
    Astellas-Quintiles Alliance Establishes Market Leadership Platform for Vesicare

  • Gain Capital & Retain Value

    March 24, 2009
    Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product.

  • Matching Risks with Rewards

    March 24, 2009
    A global pharmaceutical company had a new formulation of a core strategic asset half way through its pivotal Phase III studies, but another major product launch at the company was generating such significant expenses that it was squeezing the budget for this and other development programs.

  • Jumpstarting a Phase III Candidate

    March 24, 2009
    A global pharmaceutical company had a promising new formulation of a marketed product in early Phase III trials, but R&D budget pressures were likely to result in delays getting the product to market.

Page 1 of 1 (7 results)

Subscribe to Email Based on Your Interests

Set preferences